Understanding Primary Lateral Sclerosis (PLS)
At a Glance
Primary lateral sclerosis is a rare, slowly progressive disease affecting movement-control nerve cells in the brain and spinal cord. It usually progresses more slowly than ALS, but stiffness, disability, swallowing, and breathing problems still require specialist monitoring.
Receiving a diagnosis of Primary Lateral Sclerosis (PLS) often marks the end of a long and confusing search for answers. Because PLS is rare and its symptoms develop slowly, many patients spend years visiting different specialists before reaching this point [1][2]. This page is designed to help you understand what is happening in your body and how this condition differs from other motor neuron diseases.
What is Primary Lateral Sclerosis?
PLS is a disease that affects the upper motor neurons. These are specialized nerve cells in your brain that act like the “command center” for movement. They send signals down through your spinal cord to tell your muscles what to do [3][4].
In PLS, these upper motor neurons gradually wear out and stop communicating effectively. This leads to spasticity—a medical term for muscle stiffness and tightness—as well as weakness and slowed movement [5].
It is helpful to contrast PLS with other conditions by looking at two different sets of nerves:
- Upper Motor Neurons (The Command Center): These stay within the brain and spinal cord. PLS is primarily a disease of these neurons [3].
- Lower Motor Neurons (The Delivery Team): These nerves travel from the spinal cord out to the actual muscles. In diseases like Amyotrophic Lateral Sclerosis (ALS), both sets of neurons fail. In PLS, the lower motor neurons generally remain healthy and functional [6][7].
A Rare and Unique Path
PLS is significantly rarer than ALS. While ALS affects approximately 1.3 to 1.7 people per 100,000 each year, estimates from European registries suggest the incidence of PLS is much lower, ranging from roughly 0.084 to 0.544 per 100,000 person-years [8][9].
Because of this rarity, it is completely normal to feel a complex mix of emotions. You may feel a sense of “diagnostic relief” that you do not have the more rapid progression of ALS, yet also feel profound anxiety or isolation because your condition is so uncommon [10][1]. The uncertainty of a rare diagnosis can be an emotional burden, and many patients find that specialized psychological support is a vital part of their care [3][11].
Looking Ahead: Progression and Prognosis
The most important distinction between PLS and ALS is the speed of the disease. PLS is a much slower process. While ALS typically has a median survival of roughly 2 to 5 years from symptom onset, people with PLS often live for decades [12][13]. One specialist study found a median survival of over 23 years from the time symptoms first appeared [13], though survival is highly variable and depends on many factors.
However, “slower” does not mean “stopped,” and preserved life expectancy does not mean preserved function. Over many years, disability can accumulate. You may eventually need mobility aids like a cane or a wheelchair, or experience changes in your speech and swallowing [13][14]. Bulbar complications, such as aspiration and respiratory decline, can become medically serious even in slowly progressive disease. Because the disease moves slowly, your care team has more time to adapt your treatment to your specific needs.
When to Seek Urgent Care
Because PLS is defined by its slow, gradual progression, any “sudden” or “acute” change is not typical and requires immediate medical attention. Typical PLS progression feels like a gradual increase in stiffness over months or years, not hours or days.
Call your clinic promptly (within a few days) if you notice:
- A “wet” or gurgly voice after eating or drinking.
- Increasing coughing or choking with meals.
- Unexplained weight loss or signs of dehydration.
- Recurrent chest infections.
- New breathlessness when lying flat (orthopnea), morning headaches, or unusual daytime sleepiness [7].
Seek immediate emergency evaluation if you experience:
- Sudden respiratory distress: Severe difficulty breathing or feeling like you cannot get enough air [7].
- Severe sudden choking: A sudden inability to clear your airway or swallow saliva.
- Sudden inability to move: A rapid loss of function in a limb that happens overnight or over a few days [15].
The Importance of Specialized Care
Because PLS is so rare, many local neurologists may only see one or two cases in their entire career. This makes it critical to seek care at a specialized motor neuron disease clinic [3][4].
A specialized clinic offers a multidisciplinary team—including neurologists, physical therapists, speech-language pathologists, and respiratory therapists—who understand the specific nuances of PLS. They can provide:
- Expert Confirmation: Because PLS is often a “diagnosis of exclusion,” experts will re-evaluate your symptoms over time to ensure the diagnosis remains accurate [16][2].
- Symptom Management: Specialized teams are better equipped to manage the specific types of stiffness (spasticity) that are hallmarks of PLS [17].
- Proactive Monitoring: They will perform regular checks on your breathing and nutrition to catch and address small changes before they become problems [3].
Common questions in this guide
How is primary lateral sclerosis different from ALS?
What is the usual life expectancy with primary lateral sclerosis?
What symptoms may appear as PLS progresses?
When should someone with PLS seek urgent medical care?
Why is a specialized motor neuron disease clinic helpful for PLS?
How is PLS confirmed, and what do probable and definite PLS mean?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Primary lateral sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are my specific findings on EMG, and why does this point to PLS rather than ALS?
- 2.How much experience does this clinic have with Primary Lateral Sclerosis specifically?
- 3.Is my current disease duration sufficient for a 'definite' PLS diagnosis, or am I currently considered to have 'probable' PLS?
- 4.What is the plan for monitoring my breathing and swallowing over the next few years?
- 5.Who on my care team should I contact if I notice a sudden change in my symptoms?
- 6.Are there specific physical or occupational therapy exercises that can help manage my stiffness (spasticity)?
References
References (17)
- 1
Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?
Finegan E, Chipika RH, Shing SLH, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2019; (20(3-4)):133-145 doi:10.1080/21678421.2018.1550518.
PMID: 30654671 - 2
Diagnostic Revision From Primary Lateral Sclerosis to Amyotrophic Lateral Sclerosis: A Cohort Study.
de Boer EMJ, Willemse SW, Veldink JH, et al.
Neurology 2026; (106(12)):e218055 doi:10.1212/WNL.0000000000218055.
PMID: 42214042 - 3
Primary Lateral Sclerosis French National Diagnostic and Care Protocol.
Corcia P, Bernard E, de la Cruz E, et al.
Revue neurologique 2026; (182(6)):555-562 doi:10.1016/j.neurol.2026.04.006.
PMID: 42168009 - 4
Primary lateral sclerosis: diagnosis and management.
Turner MR, Talbot K
Practical neurology 2020; (20(4)):262-269 doi:10.1136/practneurol-2019-002300.
PMID: 32217663 - 5
The Upper Motor Neuron-Improved Knowledge from ALS and Related Clinical Disorders.
Menon P, Vucic S
Brain sciences 2021; (11(8)) doi:10.3390/brainsci11080958.
PMID: 34439577 - 6
TDP-43 pathology in primary lateral sclerosis.
Mackenzie IRA, Briemberg H
Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(sup1)):52-58 doi:10.1080/21678421.2020.1790607.
PMID: 32657153 - 7
Neurophysiological features of primary lateral sclerosis.
de Carvalho M, Kiernan MC, Pullman SL, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(sup1)):11-17 doi:10.1080/21678421.2020.1837174.
PMID: 33602011 - 8
Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.
Barceló MA, Povedano M, Vázquez-Costa JF, et al.
Scientific reports 2021; (11(1)):6207 doi:10.1038/s41598-021-85395-z.
PMID: 33737526 - 9
The Epidemiology of Primary Lateral Sclerosis: Results from a Population-Based Cohort.
Vasta R, Matteoni E, Pellegrino G, et al.
Annals of neurology 2026; (99(3)):606-613 doi:10.1002/ana.78105.
PMID: 41316718 - 10
Early Cognitive and Behavioral Changes in Primary Lateral Sclerosis: A Population-Based Study.
Calvo A, Moglia C, Canosa A, et al.
European journal of neurology 2026; (33(8)):e70720 doi:10.1111/ene.70720.
PMID: 42538773 - 11
Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.
Gould RL, McDermott CJ, Thompson BJ, et al.
Lancet (London, England) 2024; (403(10442)):2381-2394 doi:10.1016/S0140-6736(24)00533-6.
PMID: 38735299 - 12
Guideline "Motor neuron diseases" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie).
Petri S, Grehl T, Grosskreutz J, et al.
Neurological research and practice 2023; (5(1)):25 doi:10.1186/s42466-023-00251-x.
PMID: 37316950 - 13
Progression and life expectancy in primary lateral sclerosis.
Lester DG, Thompson AG, Talbot K, Turner MR
Journal of neurology, neurosurgery, and psychiatry 2025; (96(10)):1008-1011 doi:10.1136/jnnp-2025-336037.
PMID: 40379483 - 14
Natural History of "Pure" Primary Lateral Sclerosis.
Hassan A, Mittal SO, Hu WT, et al.
Neurology 2021; (96(17)):e2231-e2238 doi:10.1212/WNL.0000000000011771.
PMID: 33637635 - 15
Primary lateral sclerosis: consensus diagnostic criteria.
Turner MR, Barohn RJ, Corcia P, et al.
Journal of neurology, neurosurgery, and psychiatry 2020; (91(4)):373-377 doi:10.1136/jnnp-2019-322541.
PMID: 32029539 - 16
Primary Lateral Sclerosis: Implications for Diagnostic Criteria From a Natural History Study in the Netherlands.
de Vries BS, de Boer EMJ, Brugman F, et al.
Neurology 2025; (104(11)):e213461 doi:10.1212/WNL.0000000000213461.
PMID: 40388677 - 17
Clinical care and therapeutic trials in PLS.
Floeter MK, Warden D, Lange D, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(sup1)):67-73 doi:10.1080/21678421.2020.1837180.
PMID: 33602017
This page explains Primary Lateral Sclerosis, its typical progression, warning signs, and specialized care for educational purposes only; it does not replace medical advice. Contact your neurologist or emergency services about new or sudden symptoms.